Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Epaminontas Samantas et al.|ESMO Open|2021Cited by 93
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C. Bendell, Michael Thomas, Thomas Zander et al.|Investigational New Drugs|2019Cited by 30